BDTX

Black Diamond Therapeutics to Host Webcast Presentation of Data From Phase 1 Dose-Escalation Portion of MasterKey-01 Clinical Trial

Black Diamond Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update

Black Diamond Therapeutics to Present Phase 1 BDTX-189 Data in Advanced Solid Tumors at American Society of Clinical Oncology

Black Diamond Therapeutics Announces Preclinical Data Presentations on BDTX-189 and BDTX-1535 at American Association for Cancer Research Annual Meeting

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

Black Diamond Therapeutics to Present Pre-Clinical Data on BDTX-189 and BDTX-1535 at American Association for Cancer Research Annual Meeting

Black Diamond Therapeutics Announces Pre-Clinical Data Presentations on New Programs Targeting BRAF and FGFR at ESMO TAT Virtual Congress 2021